Ticker

Investors need to pay close attention to HROW stock based on the movements in the options market lately.

Harrow (NASDAQ: HROW - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at BTIG Research in a research note issued to investors on Wednesday, Benzinga reports. They presently have a $63.00 target price on the stock. BTIG Research's price objective indicates a potential upside of 106.19% from the company's current price. Several

First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow's Growing Ocular Surface Franchise First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow's Growing Ocular Surface Franchise

Shares of Harrow, Inc. (NASDAQ: HROW - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten ratings firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and seven have assigned a buy recommendation to the

NASHVILLE, Tenn., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that 15 scientific abstracts featuring data from across its ophthalmic portfolio will be presented at two major eyecare meetings: American Academy of Optometry's (AAOpt) Annual meeting taking place September 30 – October 3, 2026, in Anaheim,…